News
The biotech says sales of its first commercial therapy, Ryoncil, were $20 million in the quarter ending June 30.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback